Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Explore using credit card points for gift cards and enjoy easy rewards. Discover how to make the most of your points.
17,821 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
A focused $8 million investment could trigger a dramatic move in a biotech stock. Learn how three NDA filings and a d...
1Win expands its prediction markets to include crypto forecasts, introducing binary bets on XRP, DOGE, SOL, and HYPE ...
A hedge fund just trimmed a large stake in NCR Voyix, but does that spell change for ordinary investors? This guide b...
Esther Perel warns that social atrophy is creeping through workplaces, a trend accelerated by AI and hybrid schedules...
Investors have watched Peloton stumble from its pandemic-era peak to today’s volatile trading. This guide digs into w...
Alphabet’s cloud momentum is reshaping the risk-and-reward profile for investors. This article explains why the googl...
Is micron stock now? A thoughtful, numbers-informed look at memory demand, AI-driven growth, and how to decide if Mic...
What makes a stock push to all-time highs before the calendar flips? This guide breaks down the catalysts, valuation,...
Sheryl Sandberg delivers a blunt critique of Silicon Valley's workplace climate, calling hypermasculine rhetoric amon...
In 2026, the $2,000 social security check is the main retirement income for many low- and middle-income Americans. Th...
A prominent investor dumped a multi‑million stake in a biotech stock that’s up double digits. This article explains w...